Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
43.02 USD | +0.63% | -2.39% | -10.14% |
03/05 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
02/05 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.14% | 3.55B | |
+8.98% | 105B | |
-1.13% | 104B | |
+5.79% | 22.94B | |
-11.96% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-10.12% | 16.96B | |
+7.39% | 14.16B | |
+39.76% | 12.63B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical : Goldman Sachs Adjusts Ultragenyx Pharmaceutical PT to $153 From $155, Maintains Neutral Rating